| Active substance | maralixibat chloride |
| Holder | Mirum Pharmaceuticals International B.V. |
| Status | Running |
| Indication | treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS) 2 months of age and older |
| Public documents | Approbation |
| Information for the patient | |
| Informed consent | |
| Last update | 20/06/2023 |